Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
|Articles|April 8, 2022
Supplements and Featured Publications
- ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis
ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis
Advertisement
This publication was sponsored and written in partnership with Bristol Myers Squibb.
This Clinical Brief provides key information on sphingosine 1-phosphate receptor modulators for relapsing forms of multiple sclerosis (MS), including results from the phase 3 SUNBEAM and RADIANCE trials for ZEPOSIA® (ozanimod). An interview with Dr Jeffrey English, MD, of the Multiple Sclerosis Center of Atlanta offers insights on the evolution of treatments for MS, access to treatment, and disease management.
Advertisement
Related to this article
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5